Last reviewed · How we verify

Insulin Humulin® NPH — Competitive Intelligence Brief

Insulin Humulin® NPH (Insulin Humulin® NPH) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intermediate-acting human insulin. Area: Diabetes.

phase 3 Intermediate-acting human insulin Insulin receptor (IR) Diabetes Biologic Live · refreshed every 30 min

Target snapshot

Insulin Humulin® NPH (Insulin Humulin® NPH) — Geropharm. Insulin Humulin NPH is a human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Insulin Humulin® NPH TARGET Insulin Humulin® NPH Geropharm phase 3 Intermediate-acting human insulin Insulin receptor (IR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intermediate-acting human insulin class)

  1. Geropharm · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Insulin Humulin® NPH — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-humulin-nph. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: